Randomized phase 2a study of TAS5315, a Bruton's tyrosine kinase inhibitor, for chronic spontaneous urticaria.
- DOI
- 10.1016/j.alit.2026.06.003
- Published
- 2026 Jul 14
- Container
- Allergology international : official journal of the Japanese Society of Allergology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.alit.2026.06.003,
title = {Randomized phase 2a study of TAS5315, a Bruton's tyrosine kinase inhibitor, for chronic spontaneous urticaria.},
author = {Hide M and Fukunaga A and Hayama K and Inomata N and Takahagi S and Omi T and Igarashi M and Maruyama R and Yagami A},
year = {2026},
journal = {Allergology international : official journal of the Japanese Society of Allergology},
doi = {10.1016/j.alit.2026.06.003},
url = {https://doi.org/10.1016/j.alit.2026.06.003}
}RIS
TY - JOUR TI - Randomized phase 2a study of TAS5315, a Bruton's tyrosine kinase inhibitor, for chronic spontaneous urticaria. AU - Hide M AU - Fukunaga A AU - Hayama K AU - Inomata N AU - Takahagi S AU - Omi T AU - Igarashi M AU - Maruyama R AU - Yagami A PY - 2026 JO - Allergology international : official journal of the Japanese Society of Allergology DO - 10.1016/j.alit.2026.06.003 UR - https://doi.org/10.1016/j.alit.2026.06.003 ER -
APA
M, H., A, F., K, H., N, I., S, T., T, O., M, I., R, M., & A, Y. (2026). Randomized phase 2a study of TAS5315, a Bruton's tyrosine kinase inhibitor, for chronic spontaneous urticaria.. Allergology international : official journal of the Japanese Society of Allergology. https://doi.org/10.1016/j.alit.2026.06.003
Source records
- pubmed · retrieved 2026-09-26T21:45:37.483Z